Skip to main content

Table 3 Clinical and echocardiographic findings of Group III patients (n = 41) in the two treatment groups

From: Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study

Characteristics

Placebo (n = 21)

 

Rosuvastatin (n = 20)

 

p value

 

Baseline

Followup

Baseline

Followup

 

Age, y

58 ± 11

 

53 ± 16

 

0.22

Hemodynamics

     

HR (bpm)

74 ± 11

72 ± 12

71 ± 10

70 ± 7

0.38

SBP (mm Hg)

129 ± 16

127 ± 14

133 ± 15

130 ± 14

0.54

DBP (mm Hg)

80 ± 9

77 ± 10

78 ± 10

76 ± 7

0.62

Aortic Valve Parameters

     

AVA (cm2)

1.2 ± 0.4

1.1 ± 0.6

1.3 ± 0.5

1.1 ± 0.5

0.67

AV peak velocity (m/s)

3.7 ± 0.2

4.4 ± 0.5*

3.7 ± 0.1

4.4 ± 0.5†

0.88

AV peak gradient (mm Hg)

56 ± 4

80 ± 19*

56 ± 4

79 ± 16†

0.85

AV mean gradient (mm Hg)

32 ± 5

47 ± 14*

32 ± 4

46 ± 12†

0.76

Left Heart Dimensions

     

IVS (mm)

12 ± 2

12 ± 2

12 ± 2

12 ± 3

0.89

PWT (mm)

11 ± 2

12 ± 2

11 ± 1

11 ± 2

0.58

LA (mm)

36 ± 6

37 ± 7

37 ± 6

39 ± 7

0.58

LVEDD (mm)

48 ± 4

47 ± 5

50 ± 5

49 ± 6

0.86

LVESD (mm)

28 ± 5

27 ± 5

30 ± 5

30 ± 6

0.56

LV mass/BSA (g/m2)

     

   Men

94 ± 19

93 ± 17

94 ± 20

95 ± 11

0.54

   Women

81 ± 12

82 ± 15

82 ± 11

81 ± 17

0.68

EF (%)

67 ± 7

67 ± 7

68 ± 8

69 ± 8

0.54

Conventional Diastolic Parameters

     

Mitral E velocity (cm/sec)

83 ± 17

83 ± 26

84 ± 26

83 ± 27

0.44

Mitral A velocity (cm/sec)

80 ± 27

80 ± 29

80 ± 27

79 ± 41

0.77

E/A ratio

1.0 ± 0.2

1.0 ± 0.2

1.0 ± 0.2

1.0 ± 0.3

0.75

Tissue Doppler Imaging

     

Lateral S'

8.1 ± 2.7

8.1 ± 1.7

8.3 ± 1.7

8.2 ± 1.6

0.62

Lateral E'

6.0 ± 1.2

6.1 ± 2.1

6.1 ± 2.4

6.1 ± 1.3

0.74

Lateral A'

10.1 ± 3.1

9.4 ± 3.5

10.6 ± 3.6

10.3 ± 2.3

0.55

E/E' (lateral)

14 ± 3

15 ± 2

14 ± 5

15 ± 4

0.77

  1. Values are mean ± SD (percentage). y, years; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; bpm, beats per minute; AVA, aortic valve area; AV, aortic valve; IVS, interventricular septum; PWT, posterior wall thickness; LA; left atrium diameter in anterior-posterior dimension; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; LV, left ventricular; BSA, body surface area; EF, ejection fraction; S', systolic annular velocity; E', early diastolic annular velocity; A', late diastolic annular velocity. p < 0.05* was considered significant comparing baseline and follow-up values within the placebo arm. p < 0.05† was considered significant comparing baseline and follow-up values within the rosuvastatin arm. Overall p values are listed for the difference of baseline and follow-up measurements comparing placebo vs. rosuvastatin, with p < 0.05‡ considered significant.